Disease: Muscle-Invasive Bladder Cancer, MIBC, (NCT02863913)

Q: What is the treatment for?

Read more here The bladder is a muscular organ in the lower abdomen that stores urine until it can be removed (excreted) from the body. Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply uncontrollably to form a tumor. The most common type of bladder cancer, called non-muscle invasive bladder cancer (NMIBC), involves cells lining the inside of the bladder. NMIBC generally does not spread to other tissues (metastasize), but it often does recur after it has been treated. The other type, called muscle-invasive bladder cancer (MIBC), involves cells of the muscle wall of the bladder. MIBC generally does metastasize and is often life-threatening.

Q: Where does the clinical trial take place?

Read more here China, Beijing Department of Urology Peking University First Hospital, Beijing, Beijing, China, 100034

Disease info:

The bladder is a muscular organ in the lower abdomen that stores urine until it can be removed (excreted) from the body.

Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply uncontrollably to form a tumor.

The most common type of bladder cancer, called non-muscle invasive bladder cancer (NMIBC), involves cells lining the inside of the bladder. NMIBC generally does not spread to other tissues (metastasize), but it often does recur after it has been treated.

The other type, called muscle-invasive bladder cancer (MIBC), involves cells of the muscle wall of the bladder. MIBC generally does metastasize and is often life-threatening.

Frequency:

Bladder cancer occurs four times more often in men than in women. In the United States about 60,000 men and 18,000 women are diagnosed with the condition each year.

Official title:

A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Muscle-invasive Bladder Cancer

Who:

Sponsor:

Peking University

Partners:

Locations:

China, Beijing

Department of Urology Peking University First Hospital, Beijing, Beijing, China, 100034

Study start:

Sep. 1, 2016

Enrollment:

0 participants

Gene editing method:

CRISPR-Cas9

Type of edit:

Gene knock-out

Gene:

Programmed cell death protein 1 (PDCD1)

Delivery method:

- Ex-vivo

Trial link:

https://clinicaltrials.gov/ct2/show/record/NCT02863913

Safety updates:

(01-05-2016) Immune checkpoint blockade therapy for bladder cancer treatment

Disease: Muscle-Invasive Bladder Cancer, MIBC, (NCT02863913)

Company